NCT04806035 2024-07-31Study of TG-1801 Alone or in Combination With Ublituximab in Subjects With B-Cell Lymphoma or Chronic Lymphocytic LeukemiaTG Therapeutics, Inc.Phase 1 Terminated21 enrolled